Incyte Corp. (INCY)
123.22
-1.15
(-0.92%)
USD |
NASDAQ |
Aug 31, 16:00
123.00
-0.22
(-0.18%)
After-Hours: 07:07
Incyte Research and Development Expense (Annual) : 1.984B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 1.984B |
| December 31, 2024 | 2.607B |
| December 31, 2023 | 1.628B |
| December 31, 2022 | 1.586B |
| December 31, 2021 | 1.458B |
| December 31, 2020 | 2.216B |
| December 31, 2019 | 1.154B |
| December 31, 2018 | 1.198B |
| December 31, 2017 | 1.326B |
| December 31, 2016 | 581.86M |
| December 31, 2015 | 479.51M |
| December 31, 2014 | 347.52M |
| December 31, 2013 | 260.44M |
| December 31, 2012 | 210.39M |
| December 31, 2011 | 151.72M |
| December 31, 2010 | 99.40M |
| December 31, 2009 | 102.75M |
| Date | Value |
|---|---|
| December 31, 2008 | 133.29M |
| December 31, 2007 | 91.93M |
| December 31, 2006 | 80.18M |
| December 31, 2005 | 87.43M |
| December 31, 2004 | 74.36M |
| December 31, 2003 | 116.24M |
| December 31, 2002 | 152.37M |
| December 31, 2001 | 213.34M |
| December 31, 2000 | 192.56M |
| December 31, 1999 | 146.83M |
| December 31, 1998 | 108.17M |
| December 31, 1997 | 68.93M |
| December 31, 1996 | 40.86M |
| December 31, 1995 | 18.04M |
| December 31, 1994 | 10.52M |
| December 31, 1993 | 3.999M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Mirum Pharmaceuticals, Inc. | 185.83M |
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| Eli Lilly & Co. | 13.34B |
| AbbVie, Inc. | 8.249B |
| Biogen, Inc. | 1.481B |